Navigation Links
Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
Date:7/30/2009

SEATTLE, July 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for its second quarter and six months ended June 30, 2009, after the close of market on Aug. 6, 2009. The company's earnings conference call will take place Aug. 6, 2009 at 2 p.m. Pacific Time, 5 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

The live event will be available for viewing on Trubion's website at http://investors.trubion.com.

Second Quarter and First Half 2009 Earnings Conference Call: 2 p.m. PDT / 5 p.m. EDT, Aug. 6, 2009

Trubion will host a conference call and webcast to discuss its second quarter and first half 2009 financial results. The call will be held Aug. 6 at 2 p.m. PDT (5 p.m. EDT). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling 1 (719) 325-4854 or 1 (877) 440-5785. A replay of the discussion will be available beginning the evening of Aug. 6 on Trubion's website or by calling 1 (719) 457-0820 or 1 (888) 203-1112, and entering 9291496. The telephone replay will be available until midnight EDT, Thursday, Aug. 13, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1 / 2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the Company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

TRBN-G

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com

    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
11. Trubion Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads announces ... the secure online PatientCrossroads platform, has exceeded both its one-year and overall recruitment ... PROMPT study, which seeks to advance understanding of the hereditary risks for certain ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... regenerative medicine, has announced a new agreement with Singapore-based Global Stem Cells Network ... from the Philippines, Thailand and Singapore in the latest adipose and bone marrow ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... current winner of the Highest Overall Customer Rating Award from Circuits Assembly , ... business units across the USA, Canada, Mexico and China. , The EMS provider, ...
(Date:2/9/2016)... N.J. , Feb. 9, 2016  Regenicin, ... biotechnology company specializing in the development and commercialization ... of damaged tissues and organs, recently reported the ... the first quarter of 2016. Lonza ... the new 2015 fiscal year in the process ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... 2, 2016  Based on its recent analysis ... recognizes US-based Intelligent Retinal Imaging Systems (IRIS) with ... for New Product Innovation. IRIS, a prominent cloud-based ... America , is poised to set the ... retinopathy market. The IRIS technology presents superior price-performance ...
Breaking Biology News(10 mins):